Capvizr
THE DEAL, AT A GLANCE

Liflex

From the announcement
01
MoleculesDrug research
Medicine development
What it doesOverview Liflex Science is a South Korean biotechnology company developing RNA-based therapeutics for degenerative arthritis and other musculoskeletal disease…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
02Who is involvedBacked by Jin-Hong Kim, Dong-Soon Ahn (From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
03What happenedLiflex raised $5.3M Series A, announced 2026-11-13From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
04Why it mattersLiflex raised a $5.25M Series A in a financing tracked as Unclassified.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Liflex · Financing Record

Explore source-linked visual explanations for Liflex. Unsupported claims are withheld while source review continues.

Record 15944 · Recorded date: 2026-11-13

What it does

Liflex, image from liflex.com.br

Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.

Open record 15944 →

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime